Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 mei 2013 - 07:22
Statutaire naam
Galapagos NV
Titel
AbbVie and Galapagos extend GLPG0634 collaboration to include Crohn's disease
Bericht
* First selective JAK1 inhibitor to enter Phase 2 studies in Crohn's disease
* Galapagos to fund and complete Phase 2 study; AbbVie to pay Galapagos $50 million upon successful completion, expected in 2015
North Chicago, USA and Mechelen, Belgium; 17 May 2013 - Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the study, expected in Q2 2015, AbbVie will pay Galapagos $50 million. The terms of the collaboration extension are in addition to previously agreed upon financial terms. AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities.
Datum laatste update: 01 september 2024